SCHEMBL25328598

SCHEMBL25328598

COc1cc(/C=C/C=C/c2ccc(O)cc2)cc(OC)c1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 6/20 0.86
CYP1B1 Q16678 6/20 0.86
PTGS2 P35354 4/20 0.86
ALOX5 P09917 4/20 0.86
NQO2 P16083 4/20 0.86
TTR P02766 3/20 0.86
ABL1 P00519 3/20 0.86
BCR P11274 3/20 0.86
KDM4E B2RXH2 3/20 0.86
ABCB1 P08183 2/20 0.86
PTGS1 P23219 2/20 0.86
MEN1 O00255 2/20 0.86
MAPT P10636 2/20 0.86
KMT2A Q03164 2/20 0.86
NPC1 O15118 1/20 0.86
GAA P10253 1/20 0.86
MAPK1 P28482 1/20 0.86
RAB9A P51151 1/20 0.86
GFER P55789 1/20 0.86
HDAC6 Q9UBN7 1/20 0.86

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pterostilbene SCHEMBL20063 0.92 CYP1A1 (1.00) CYP1A1CYP1B1PTGS2ALOX5NQO2
Pterostilbene SCHEMBL3545782 0.92 CYP1A1 (1.00) CYP1A1CYP1B1PTGS2ALOX5NQO2
Pterostilbene SCHEMBL28222684 0.92 CYP1A1 (1.00) CYP1A1CYP1B1PTGS2ALOX5NQO2
Pterostilbene SCHEMBL563218 0.92 CYP1A1 (1.00) CYP1A1CYP1B1PTGS2ALOX5NQO2
SCHEMBL562336 0.87 CYP1A1 (1.00) CYP1A1CYP1B1PTGS2ALOX5NQO2
SCHEMBL30475363 0.87 CYP1A1 (1.00) CYP1A1CYP1B1PTGS2ALOX5NQO2
SCHEMBL562335 0.87 CYP1A1 (1.00) CYP1A1CYP1B1PTGS2ALOX5NQO2
SCHEMBL5809455 0.86 CYP1A1 (0.84) CYP1A1CYP1B1PTGS2ALOX5NQO2
SCHEMBL5809462 0.86 CYP1A1 (0.84) CYP1A1CYP1B1PTGS2ALOX5NQO2
Pterostilbene SCHEMBL3476943 0.86 NQO2 (0.86) CYP1A1CYP1B1PTGS2ALOX5NQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466784-B2 Analogs of pterostilbene amino acid bearing carbonates for treating a non-alcoholic fatty liver disease and nonalcoholic steatohepatitis APICAL MOLECULAR BIOTECH CO., LTD. (TW) 2025-11-11 US disclosed
EP-4136063-B1 NOVEL ANALOGS OF PTEROSTILBENE AMINO ACID BEARING CARBONATES FOR TREATING A NON-ALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS APICAL MOLECULAR BIOTECH CO LTD (TW) 2025-10-22 EP disclosed
US-20230234912-A1 NOVEL ANALOGS OF PTEROSTILBENE AMINO ACID BEARING CARBONATES FOR TREATING A NON-ALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS APICAL MOLECULAR BIOTECH CO., LTD. (TW) 2023-07-27 US disclosed
CN-115835860-A Novel analogues of pterostilbene amino acids with carbonate for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis 树顶分子生技股份有限公司 2023-03-21 CN disclosed
EP-4136063-A1 NOVEL ANALOGS OF PTEROSTILBENE AMINO ACID BEARING CARBONATES FOR TREATING A NON-ALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS Apical Molecular Biotech. Co., Ltd. (TW) 2023-02-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234912-A1 NOVEL ANALOGS OF PTEROSTILBENE AMINO ACID BEARING CARBONATES FOR TREATING A NON-ALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS FABP1, GLS2, SLC1A5 CYP1A1 2749/4885CYP1B1 2382/4885PTGS2 981/4885
US-12466784-B2 Analogs of pterostilbene amino acid bearing carbonates for treating a non-alcoholic fatty liver disease and nonalcoholic steatohepatitis FABP1, GLS2, SLC1A5 CYP1A1 2681/4885CYP1B1 2314/4885PTGS2 828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.